Abstract
We have coined the term “Malignant Obesity Hypoventilation Syndrome” (MOHS) to describe a severe multisystem disease due to the systemic effects of obesity. Patients with this syndrome have severe obesity related hypoventilation together with systemic hypertension, diabetes and the metabolic syndrome, left ventricular hypertrophy with diastolic dysfunction, pulmonary hypertension and hepatic dysfunction. Patients with MOHS are frequently admitted to the ICU with hypercapnic respiratory failure and have a high mortality. This syndrome is largely unrecognized as physicians do not make the association between the patients’ multiple medical problems and obesity. Due to the delayed diagnosis and progressive morbidities of this condition all patients with a BMI > 40 kg/m2 should be screened for MOHS. The management of patients with MOHS includes short term measures to improve the patients’ medical condition and long term measures to achieve enduring weight loss. Bariatric surgery reverses or improves the multiple metabolic and organ dysfunctions associated with MOHS and should be strongly considered in these patients.
Keywords: Diabetes, diastolic heart failure, metabolic syndrome, myocardial hypotrophy, non-acholic steato-hepatitis, obesity, obesity hypoventilation syndrome, pulmonary hypertension.
Current Respiratory Medicine Reviews
Title:The Malignant Obesity Hypoventilation Syndrome (MOHS)
Volume: 10 Issue: 4
Author(s): Paul E. Marik and Joseph Varon
Affiliation:
Keywords: Diabetes, diastolic heart failure, metabolic syndrome, myocardial hypotrophy, non-acholic steato-hepatitis, obesity, obesity hypoventilation syndrome, pulmonary hypertension.
Abstract: We have coined the term “Malignant Obesity Hypoventilation Syndrome” (MOHS) to describe a severe multisystem disease due to the systemic effects of obesity. Patients with this syndrome have severe obesity related hypoventilation together with systemic hypertension, diabetes and the metabolic syndrome, left ventricular hypertrophy with diastolic dysfunction, pulmonary hypertension and hepatic dysfunction. Patients with MOHS are frequently admitted to the ICU with hypercapnic respiratory failure and have a high mortality. This syndrome is largely unrecognized as physicians do not make the association between the patients’ multiple medical problems and obesity. Due to the delayed diagnosis and progressive morbidities of this condition all patients with a BMI > 40 kg/m2 should be screened for MOHS. The management of patients with MOHS includes short term measures to improve the patients’ medical condition and long term measures to achieve enduring weight loss. Bariatric surgery reverses or improves the multiple metabolic and organ dysfunctions associated with MOHS and should be strongly considered in these patients.
Export Options
About this article
Cite this article as:
E. Marik Paul and Varon Joseph, The Malignant Obesity Hypoventilation Syndrome (MOHS), Current Respiratory Medicine Reviews 2014; 10 (4) . https://dx.doi.org/10.2174/1573398X11666150427223059
DOI https://dx.doi.org/10.2174/1573398X11666150427223059 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Circulating Biomarkers of Collagen Metabolism and Prognosis of Heart Failure with Reduced or Mid-Range Ejection Fraction
Current Pharmaceutical Design Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design Cardiac (myo)fibroblast: Novel Strategies for its Targeting Following Myocardial Infarction
Current Pharmaceutical Design Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets Sleep-Disordered Breathing and Cardiovascular Disease: Exploring Pathophysiology and Existing Data
Current Respiratory Medicine Reviews Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors
Current Medicinal Chemistry Recent Patents in Cardiac Resynchronization Therapy
Recent Patents on Biomedical Engineering (Discontinued) Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology Metabolomics and Heart Diseases: From Basic to Clinical Approach
Current Medicinal Chemistry G Protein-Coupled Receptors – Potential Roles in Clinical Pharmacology
Cardiovascular & Hematological Agents in Medicinal Chemistry Long Non-Coding RNA GAS5 in Age-Related Diseases
Current Medicinal Chemistry Anticoagulation in Patients with Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry The Fundamental Role of Stress Echo in Evaluating Coronary Artery Disease in Specific Patient Populations
Current Vascular Pharmacology Subject Index to Volume 2
Current Vascular Pharmacology Why Multiples of 21? Why does Selenoprotein P Contain Multiple Selenocysteine Residues?
Current Nutraceuticals Functional Genomics in Zebrafish as a Tool to Identify Novel Antiarrhythmic Targets
Current Medicinal Chemistry Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy
Current Pharmaceutical Design Incretins Yesterday, Pleiotropic Gastrointestinal Hormones Today:Glucagon-Like Peptide-1 (GLP-1) and Glucose-ependent Insulinotropic Polypeptide (GIP)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Woman’s Heart: Insights into New Potential Targeted Therapy
Current Medicinal Chemistry Role of Oxidative Stress and Mitochondrial Dysfunction in Skeletal Muscle in Type 2 Diabetic Patients
Current Pharmaceutical Design